Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00866528 · ClinicalTrials.gov registry record · Phase 1
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00866528 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 30 participants.
The verdict
NCT00866528, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
Interventions
- DRUG paclitaxel
- DRUG pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-07-09 |
| Est. Completion | 2012-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00866528
The ClinicalTrials.gov registry entry for NCT00866528 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT00866528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00866528 about?
NCT00866528 is a clinical study titled "Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer". The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
What is the current status of trial NCT00866528?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2009-07-09. Estimated completion is 2012-10-25.
What interventions are being tested in trial NCT00866528?
The interventions under investigation include: paclitaxel (DRUG), pazopanib (DRUG).
Who is sponsoring clinical trial NCT00866528?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.